| Prev Close | 0.91 |
| Open | 0.92 |
| Day Low/High | 0.87 / 0.92 |
| 52 Wk Low/High | 0.63 / 1.50 |
| Volume | 153.08K |
| Exchange | OTC |
| Shares Outstanding | 131.38B |
| Market Cap | 105.10M |
| Div & Yield | N.A. (N.A) |
Latest News
Cellceutix Reports Very Encouraging Interim Analysis Of Phase 2 Drug Candidate Brilacidin For Severe Oral Mucositis (OM) In Head And Neck Cancer Patients; High Potential For Preventative Treatment
Study showed a markedly reduced rate of Severe OM (WHO Grade = 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)
Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Cellceutix Releases Favorable Topline Findings As Part Of Interim Analysis Of Phase 2 Drug Candidate Brilacidin For The Treatment Of Inflammatory Bowel Disease
Study results, through the first two cohorts of patients treated, support Brilacidin as a novel and promising anti-inflammatory drug candidate
Cellceutix's Phase 2 Drug Candidate Brilacidin Emerging As A Potential Novel Non-Biologic Therapy In Treating Inflammatory Bowel Disease
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease
Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix
TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.
Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags
CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.
Cellceutix Announces Business Update Call At 10AM Eastern On November 15
Management to provide Clinical, Regulatory and Financial Updates
